Skip to content

Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the efficacy in bifidobacteria on skin aging in healthy women

Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the efficacy in bifidobacteria on skin aging in healthy women - A clinical study of oral bifidobacteria intake and skin aging

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000045596
Enrollment
130
Registered
2021-09-28
Start date
2021-09-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Intake of powdered bifidobacteria for 12 weeks Intake of powdered placebo for 12 weeks

Sponsors

Juntendo university graduate school of medicine Department of Microbiota Research
Lead Sponsor
The Jikei University Kashiwa hospital
Collaborator

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Adult female aged 30 years old or older

Exclusion criteria

Exclusion criteria: Individual who is applicable to any of the conditions below; 1. Taking regular aesthetic procedure or foods (except those who are able to continuously discontinue the act during the study). 2. Having skin problems, requiring medical care to their skin or taking treatment to diseases that could have an influence on their skin. 3. Having major allergic disease or being highly likely to develop those diseases 4. Being under sever diseases or having past history of those diseases. 5. Having medication allergy or severe food allergy. 6. Regularly taking foods, medication or supplement that would have an influence on gut microbiota (4 or more days a week of intake is regarded as regular use). 7. Heavy drinker 8. Smoking more than 20 cigarettes a day 9. Pregnant, willing to pregnant during the study period and continuous breast feeding 10. Currently participating to other clinical trial or past history within a month 11. Judged as not appropriate to this study by a responsible doctor or contributing doctors

Design outcomes

Primary

MeasureTime frame
VISIA total score after oral intake of bifidobacteria

Secondary

MeasureTime frame
VISIA sub-scores, the balance of gut microbiota, the balance of skin microbiota, objective evaluation of skin condition, subjective evaluation of skin condition(VAS) after oral intake of bifidobacteria

Countries

Japan

Contacts

Public ContactYuriko Nishikawa

Juntendo university graduate school of medicine Department of Microbiota Research

ynishika@juntendo.ac.jp03(3813)3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026